Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Spero Therapeutics ( (SPRO) ) has shared an announcement.
On January 30, 2026, Spero Therapeutics announced that co‑founder Ankit Mahadevia, MD resigned from its Board of Directors, its Development Committee, and all officer and director roles at its subsidiaries, citing other professional commitments and not any disagreement over the company’s operations, policies, or practices; the company expressed gratitude for his service since inception and indicated that it plans to retain him in a consulting capacity to continue supporting management. Earlier, on January 20, 2026, Spero received notice from the U.S. Securities and Exchange Commission that the regulator had concluded its previously disclosed investigation and, based on information available as of that date, did not intend to recommend an enforcement action, a development that removes a significant regulatory overhang for the company and may improve visibility and confidence for investors and other stakeholders.
The most recent analyst rating on (SPRO) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Spero Therapeutics stock, see the SPRO Stock Forecast page.
Spark’s Take on SPRO Stock
According to Spark, TipRanks’ AI Analyst, SPRO is a Neutral.
The score is held back primarily by weak financial performance (declining revenue, large losses, and ongoing cash burn), with a mixed technical picture adding little support. A notable offset is the positive corporate event (GSK NDA resubmission and $25M milestone) and the company’s relatively low leverage, but valuation remains challenging due to negative earnings.
To see Spark’s full report on SPRO stock, click here.
More about Spero Therapeutics
Spero Therapeutics, Inc. is a biopharmaceutical company focused on developing novel therapies, including antibiotic and anti-infective treatments, targeting serious infections and unmet medical needs in the healthcare market.
Average Trading Volume: 334,867
Technical Sentiment Signal: Buy
Current Market Cap: $125.6M
For detailed information about SPRO stock, go to TipRanks’ Stock Analysis page.